- +1 305 988 8996
- Mon - Fri: 9:00 - 18:30
1Besides the Spraypen®, the Vivostat® system offers different types of applicators, e.g. the Endoscopic Applicator. For a full list of application devices click here
Unlike conventional application systems, the Vivostat® Spraypen gives the surgeon freedom to place the solution very accurately on the target site instead of the surrounding tissue. This is especially important in pin point applications, micro anastomosis and difficult to reach areas.
The great degree of accuracy enables the surgeon to make better use of the fibrin sealant/PRF® solution and improves efficiency.
Today the Concorde Spraypen® is used in a wide range of surgical procedures. With the carefully optimized angle on the spraytip, surgeons find the Concorde Spraypen® very convenient for the application of e.g. fibrin sealant on anastomosis on the backside of the heart, sealing of the marmary bed and some types of abdominal surgery in difficult to reach organs.
The Concorde Spraypen® utilizes the same unique spray nozzle as the original Spraypen®, allowing the surgeon to apply the Vivostat® solution in a precise and targeted manner throughout the entire procedure without experiencing blockage.
The single-use endoscopic application catheter is easily loaded into the endoscopic applicator handle (reusable) and the handle is inserted via a 5 mm trocar.
When using the Endoscopic Applicator, the Vivostat® solution is applied through the same unique nozzle that is also used with the Spraypen®. This allows the surgeon to apply the Vivostat® solution in a precise and targeted manner throughout the entire procedure without experiencing blockage. Due to the preformed nozzle, the spray tip can easily be manipulated in many directions giving the surgeon unparalleled freedom in control of application, unobtainable with conventional application systems.
When using the Vivostat® Endoscopic Applicator the application of fibrin or PRF® is activated by a foot switch.
However, there is an additional channel in the catheter that allows the surgeon to co-deliver a substance together with the Vivostat Fibrin Sealant or Patelet Rich Fibrin (PRF®).
With the Endoscopic Kit – Co-delivery the surgeon is able to topically co-apply the substance, for slow release from the Vivostat Fibrin Sealant or PRF® solutions. Doing this endoscopically means less stress on the patient.
When using The Vivostat® Endoscopic Straight the fibrin sealant or PRF® solution is applied through the same unique nozzle that is also used with the Vivostat® Spraypen®. This allows the surgeon to apply the Vivostat® solution in a precise and targeted manner throughout the entire procedure without experiencing blockage. When using the Vivostat® Endoscopic Straight the application of fibrin or PRF® is activated by a foot switch.
____________________________________________
↓
Comparative kinetics of polymerisation of three fibrin sealants and influence on timing of tissue adhesion · Kjaergard H K et al. · Thrombosis Research 2000; 98: 221-228
Comparative kinetics of polymerisation of three fibrin sealants and influence on timing of tissue adhesion · Kjaergard H K et al. · Thrombosis Research 2000; 98: 221-228
Comparative kinetics of polymerisation of three fibrin sealants and influence on timing of tissue adhesion · Kjaergard H K et al. · Thrombosis Research 2000; 98: 221-228
The Vivostat® Processor Unit is designed with specially developed sensors and software that carefully detect the individual patient fibrinogen level and automatically adjust the amount of diluting buffer to extract a fibrin sealant with a constant concentration of fibrinogen. In contrast the variation in fibrinogen concentration of conventional patient-derived sealants reflects the normal variation in the plasma fibrinogen level.
The constant fibrinogen concentration in Vivostat® Fibrin Sealant guarantees the same excellent physical properties from patient to patient. 
The thrombocyte solution used in these cases has traditionally been supplied by the blood bank.
Recently, a number of commercial products have entered the market with simpler and smaller devices that are still based on the same centrifugation technology. Most products still require sterile handling and have shortcomings in both the biophysical properties and the delivery system.
Vivostat has solved these problems by leveraging the revolutionary technology used in the Vivostat® system for the preparation and application of autologous fibrin sealant. By combining a fibrin sealant solution with a platelet concentrate, it is possible
to have a carrier, a controlled release and a medium for vascular ingrowth
– all in one product, Vivostat PRF® (Platelet Rich Fibrin).
Using the Vivostat® system, you can prepare autologous platelets with multiple growth factors embedded in a fibrin sealant matrix. From 120 ml blood, 5-6 ml of Platelet Rich Fibrin (PRF®) is prepared. By combining a platelet concentrate with a fibrin sealant solution, it is possible to have a carrier, a controlled release and a medium for vascular ingrowth – all in one product, Vivostat PRF®. Compared to conventional PRP products, Vivostat PRF® has a number of advantages.
With an average 7-fold increase over baseline blood levels, the platelet concentration in Vivostat PRF® exceeds the baseline platelet count of 1 million/μL, which has become a benchmark within platelet therapy. The fibrin matrix ensures a slow release of growth factors over time and effectively protects the growth factors against proteolytic degradation.
The specially designed Vivostat® Spraypen® and the unique combination of platelets and fibrin ensures easy, accurate and efficient application of Vivostat PRF®. Due to instant polymerisation and excellent adhesive properties of the fibrin component, the PRF® solution remains where it is applied – even when applied on vertical or inverted surfaces. As the fibrin component in Vivostat PRF® is based on a fibrin 1 solution, there is no need to use a separate thrombin component.
The Vivostat® system is the first and only system on the market to offer a convenient and fully automated process for the preparation of a platelet rich fibrin (PRF®).
Vivostat PRF® contains a variety of potent growth factors that stimulate fibroblast proliferation and tissue synthesis, e.g. TGF-β1,PDGF, VEGF, FGF-2 etc. Several in-vitro investigations confirm the unique characteristics of Vivostat PRF® and its ability to stimulate cell growth.
Apart from producing structural proteins such as collagen, they stimulate both angiogenesis and epithelialisation.
In-vitro studies have proven the positive effect of Vivostat PRF® on fibroblast proliferation. As illustrated, Vivostat PRF® increases the growth of normal human skin fibroblasts compared to control and performs significantly better than PDGF-BB (commercial growth factor).
Bioactivity and stability of endogenous fibrogenic factors in platelet-rich fibrin, Lundquist R. et al., Wound Repair and Regeneration 2008; 16(3): 356-63
In-vitro studies have illustrated the positive effect of Vivostat PRF® on the ability of fibroblasts to synthesise collagen. Vivostat PRF® performs better than PDGF-AB, the major PDGF isoform in human platelets. The reason for this may be that Vivostat PRF® contains multiple growth factors and not just PDGF-AB.
Bioactivity and stability of endogenous fibrogenic factors in platelet-rich fibrin, Lundquist R. et al., Wound Repair and Regeneration 2008; 16(3): 356-63
Controlling the release of platelet contents over several days requires not only a delivery media but also protection of the platelets against degradation.
The autologous fibrin matrix in Vivostat PRF® has shown to protect endogenous growth factors against proteolytic degradation and thereby preserve their biological activity.
Bioactivity and stability of endogenous fibrogenic factors in platelet-rich fibrin, Lundquist R. et al., Wound Repair and Regeneration 2008; 16(3): 356-63
Following application of the Vivostat PRF® solution, the fibrin matrix will naturally be broken down by fibrinolytic processes (fibrinolysis), and during this process the growth factors contained in the platelets are gradually released to the treatment site over a period of 4 days or more. In effect, the fibrin matrix is a delivery media that slowly releases growth factors over time.
